Tilray Brands, Inc. (TLRY)
USD 0.46
(-6.26%)
USD 0.46
(-6.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -244.98 Million USD | 83.02% |
| 2023 | -1.44 Billion USD | -232.39% |
| 2022 | -434.13 Million USD | -29.2% |
| 2021 | -336.01 Million USD | -450.69% |
| 2020 | -61.01 Million CAD | -400.36% |
| 2019 | -12.19 Million CAD | -153.4% |
| 2018 | 22.83 Million CAD | 632.79% |
| 2017 | 3.11 Million CAD | 921.38% |
| 2016 | 305.12 Thousand CAD | 105.8% |
| 2015 | -5.26 Million CAD | -12439.24% |
| 2014 | -41.98 Thousand CAD | 56.46% |
| 2013 | -96.42 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -244.98 Million USD | 83.02% |
| 2024 Q1 | -55.86 Million USD | 53.38% |
| 2024 Q2 | -49 Million USD | 12.27% |
| 2024 Q3 | -92.7 Million USD | -89.15% |
| 2024 Q4 | -31.74 Million USD | 65.75% |
| 2023 Q4 | -119.81 Million USD | 89.98% |
| 2023 Q3 | -1.19 Billion USD | -1840.05% |
| 2023 FY | -1.44 Billion USD | -232.39% |
| 2023 Q1 | -65.79 Million USD | 85.63% |
| 2023 Q2 | -61.63 Million USD | 6.32% |
| 2022 Q3 | 43.19 Million USD | 645.04% |
| 2022 Q4 | -457.8 Million USD | -1159.97% |
| 2022 FY | -434.13 Million USD | -29.2% |
| 2022 Q2 | 5.79 Million USD | 113.92% |
| 2022 Q1 | -41.64 Million USD | -223.94% |
| 2021 Q4 | 33.6 Million USD | 111.86% |
| 2021 Q1 | -3.89 Million CAD | 94.53% |
| 2021 Q2 | -92.87 Million CAD | -2284.85% |
| 2021 Q3 | -283.3 Million CAD | -205.02% |
| 2021 FY | -336.01 Million USD | -450.69% |
| 2020 Q3 | 4.25 Million CAD | 171.27% |
| 2020 FY | -61.01 Million CAD | -400.36% |
| 2020 Q1 | 12.3 Million CAD | -0.34% |
| 2020 Q4 | -71.26 Million CAD | -1775.75% |
| 2020 Q2 | -5.96 Million CAD | -148.5% |
| 2019 Q3 | -82.3 Million CAD | -299.52% |
| 2019 Q2 | 41.25 Million CAD | 153.01% |
| 2019 Q1 | 16.3 Million CAD | 495.53% |
| 2019 FY | -12.19 Million CAD | -153.4% |
| 2019 Q4 | 12.34 Million CAD | 115.0% |
| 2018 Q1 | 11.91 Million CAD | 686.38% |
| 2018 Q3 | 10.13 Million CAD | 102.01% |
| 2018 Q4 | -4.12 Million CAD | -140.68% |
| 2018 FY | 22.83 Million CAD | 632.79% |
| 2018 Q2 | 5.01 Million CAD | -57.9% |
| 2017 Q3 | 3.75 Million CAD | 433.16% |
| 2017 Q4 | -2.03 Million CAD | -154.14% |
| 2017 FY | 3.11 Million CAD | 921.38% |
| 2017 Q1 | 683.89 Thousand CAD | -29.67% |
| 2017 Q2 | 703.87 Thousand CAD | 2.92% |
| 2016 Q1 | -360.08 Thousand CAD | 14.27% |
| 2016 FY | 305.12 Thousand CAD | 105.8% |
| 2016 Q4 | 972.37 Thousand CAD | 35321.49% |
| 2016 Q3 | 2745.16 CAD | 100.85% |
| 2016 Q2 | -322.41 Thousand CAD | 10.46% |
| 2015 Q2 | -6112.93 CAD | 22.04% |
| 2015 Q1 | -7840.70 CAD | 87.46% |
| 2015 FY | -5.26 Million CAD | -12439.24% |
| 2015 Q4 | -420 Thousand CAD | 83.07% |
| 2015 Q3 | -2.48 Million CAD | -40472.45% |
| 2014 Q1 | -6954.06 CAD | -89.61% |
| 2014 Q3 | -46.54 Thousand CAD | -1137.19% |
| 2014 Q4 | -62.52 Thousand CAD | -34.35% |
| 2014 FY | -41.98 Thousand CAD | 56.46% |
| 2014 Q2 | -3761.96 CAD | 45.9% |
| 2013 FY | -96.42 Thousand CAD | 0.0% |
| 2013 Q2 | -19.48 Thousand CAD | -52.65% |
| 2013 Q3 | -12.67 Thousand CAD | 34.95% |
| 2013 Q4 | -3667.48 CAD | 71.07% |
| 2013 Q1 | -12.76 Thousand CAD | 25.74% |
| 2012 Q2 | -3424.37 CAD | 0.0% |
| 2012 Q3 | -65.34 Thousand CAD | -1808.27% |
| 2012 Q4 | -17.18 Thousand CAD | 73.7% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 1404.548% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -3012.846% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 608.734% |
| Cosmos Health Inc. | -18.54 Million USD | -1221.175% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -1121.406% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -17.077% |
| Cronos Group Inc. | -73.96 Million USD | -231.221% |
| Incannex Healthcare Limited | -18.45 Million USD | -1227.163% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -480.537% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 2139.299% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -5594.8% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -5336.72% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -5336.72% |
| SCYNEXIS, Inc. | 67.04 Million USD | 465.42% |
| Safety Shot Inc | -15.08 Million USD | -1524.215% |
| Theratechnologies Inc. | -23.95 Million USD | -922.586% |
| Alpha Teknova, Inc. | -36.78 Million USD | -566.071% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -3874.989% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 683.914% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -4966.825% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3734.419% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 75.557% |
| Radius Health, Inc. | -25.79 Million USD | -849.87% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -7806.357% |
| Alvotech | -551.73 Million USD | 55.598% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | -75.395% |
| SIGA Technologies, Inc. | 68.06 Million USD | 459.902% |
| Shineco, Inc. | -22.44 Million USD | -991.277% |
| Silver Spike Investment Corp. | 7.34 Million USD | 3437.567% |
| Journey Medical Corporation | -3.85 Million USD | -6258.188% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -2901.046% |
| Embecta Corp. | 70.4 Million USD | 447.984% |
| Harrow Health, Inc. | -24.41 Million USD | -903.568% |
| Procaps Group, S.A. | 42.54 Million USD | 675.884% |
| Biofrontera Inc. | -20.13 Million USD | -1116.934% |
| DURECT Corporation | -27.62 Million USD | -786.841% |
| PainReform Ltd. | -9.34 Million USD | -2521.8% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 18715.578% |
| OptiNose, Inc. | -35.48 Million USD | -590.418% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 1124.339% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 5054.115% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -3801.394% |
| ProPhase Labs, Inc. | -16.78 Million USD | -1359.784% |
| Phibro Animal Health Corporation | 2.41 Million USD | 10239.942% |
| Procaps Group S.A. | 42.54 Million USD | 675.884% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -2283.547% |
| Viatris Inc. | 54.7 Million USD | 547.863% |
| Rockwell Medical, Inc. | -8.43 Million USD | -2802.962% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -1446.207% |
| PetIQ, Inc. | 2.13 Million USD | 11596.058% |
| Talphera, Inc. | -18.39 Million USD | -1231.636% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 198.11% |
| Alimera Sciences, Inc. | -20.13 Million USD | -1116.874% |
| Assertio Holdings, Inc. | -331.94 Million USD | 26.198% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -3615.93% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | -52.849% |
| Hempacco Co., Inc. | -13.12 Million USD | -1766.368% |
| Alvotech | -551.73 Million USD | 55.598% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 174.995% |
| Kamada Ltd. | 8.28 Million USD | 3057.279% |
| Currenc Group, Inc. | -15.3 Million USD | -1500.498% |
| Indivior PLC | 2 Million USD | 12349.05% |
| Evoke Pharma, Inc. | -7.79 Million USD | -3043.888% |
| Flora Growth Corp. | -57.03 Million USD | -329.52% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -1121.406% |
| Evolus, Inc. | -61.68 Million USD | -297.148% |
| HUTCHMED (China) Limited | 100.78 Million USD | 343.085% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 278.11% |
| Akanda Corp. | -32.27 Million USD | -659.041% |